OR WAIT 15 SECS
© 2021 MJH Life Sciences and Modern Retina. All rights reserved.
© 2021 MJH Life Sciences™ and Modern Retina. All rights reserved.
January 01, 2021
Multiple challenges remain for diabetic macular edema with unmet needs to improve treatment outcomes, speed of treatment benefit, and the duration of response.
Three risk-related baseline factors identified by this analysis may be associated with a potential need for injections.
December 01, 2020
A study including data from about 42,000 eyes found diabetic retinopathy (DR) severity is a risk factor for the progression of diabetic eye disease. Other findings support the idea that genetic factors influence the development of proliferative DR versus diabetic macular edema.
Study highlights the role of demographic and socioeconomic characteristics as contributors to disease- and treatment-related disparities among patients with diabetic macular edema.
A panel of experts in ophthalmology and optometry review the diagnosis and treatment of diabetic eye disease including emerging agents in the field.
November 01, 2020
Results support further research investigating transforming growth factor-β-Induced Gene Human Clone 30 (BIGH3).
The benefit is robust across a variety of demographics and baseline disease characteristics, according to data.
October 01, 2020
Study offers a real-world scenario of a very specific, but frequent and crucial aspect of the care of patients with diabetes, suggests clinician
Visual acuity outcomes at 6 months’ post-treatment were similar, regardless of the use of anti-VEGF therapy.
September 01, 2020
Researchers advocate for intraoperative intravitreal steroid during cataract surgery in patients with DME.